About 30 results found for searched term "mTOR inhibitor-1" (0.107 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10271 | mTOR inhibitor-1 | mTOR |
| mTOR-IN-1 | ||
| mTOR inhibitor-1 is a potential ATP-competitive inhibitor of mTOR which could inhibit cell growth and proliferation. | ||
| M13675 | HDACs/mTOR Inhibitor 1 | HDAC |
| HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. | ||
| M43384 | mTOR inhibitor-12 | mTOR |
| mTOR inhibitor-12 is a selective brain penetrant mTOR inhibitor without genotoxicity risk. | ||
| M43385 | mTOR inhibitor-11 | mTOR |
| mTOR inhibitor-11 is a brain-penetrant mTOR inhibitor (IC50: 21 nM for pS6). | ||
| M1671 | BEZ235 | PI3K |
| NVP-BEZ235, Dactolisib | ||
| BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively. | ||
| M1731 | KU-0063794 | mTOR |
| KU-0063794 is a potent and selective mTOR inhibitor with IC50 values of approximately 10 nM for mTORC1 and mTORC2. | ||
| M1755 | WYE-354 | mTOR |
| WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP). | ||
| M2022 | Torin 2 | mTOR |
| Torin 2 is a potent and selective mTOR inhibitor with IC50 of 2.1 nM. | ||
| M2567 | VS-5584 | PI3K |
| SB2343 | ||
| VS-5584 (SB2343) is a potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively. | ||
| M3218 | PKI-402 | PI3K |
| PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R. | ||
| M3556 | WYE-125132 | mTOR |
| WYE-125132 is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR. | ||
| M3722 | Temsirolimus | mTOR |
| CCI-779; WAY-130779 | ||
| Temsirolimus (WAY-130779, CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM. | ||
| M4934 | Onatasertib (CC-223) | mTOR |
| ATG-008 | ||
| Onatasertib (CC-223) is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM). | ||
| M8395 | REDD1 inducer | Others |
| 6-(1,3-Dioxo-6-(piperidin |
||
| M10471 | MTI-31 (LXI-15029) | mTOR |
| LXI-15029; MTI31 | ||
| MTI-31 (LXI-15029) is a novel low-toxicity mTORC1/mTORC2 inhibitor, demonstrated a potent mTOR binding affinity with >5000 fold selectivity over the related PI3K family isoforms. MTI-31 inhibited mTORC1- and mTORC2 function at ≤120 nM in cellular assays. | ||
| M11541 | JR-AB2-011 | mTOR |
| Jr-ab2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. Jr-ab2-011 inhibited mTORC2 activity by blocking the Rictor-MTOR complex (Ki: 0.19 μM). Jr-ab2-011 has anti-glioblastoma multiforme (GBM) activity. | ||
| M13656 | CC-115 hydrochloride | DNA-PK |
| CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling. | ||
| M14842 | mTOR inhibitor-3 | mTOR |
| mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a Ki of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments. | ||
| M14846 | Dactolisib Tosylate | PI3K |
| BEZ235 Tosylate; NVP-BEZ 235 Tosylate | ||
| Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2. | ||
| M14852 | PI-103 Hydrochloride | PI3K |
| PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. | ||
| M14854 | PI3K/mTOR Inhibitor-2 | PI3K |
| PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity. | ||
| M21167 | RMC-5552 | mTOR |
| The selective mTORC1 complex inhibitor RMC-4529 is a bidentate inhibitor that has a rapamycin-derived, FKBP12-induced heterologous mTOR inhibitor covalently linked to an active-site (orthologous) inhibitor. | ||
| M25389 | Rheb inhibitor NR1 | mTOR |
| Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 does not influence mTORC2 activity. | ||
| M27971 | DS-7423 | PI3K |
| DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity. | ||
| M27987 | CC214-2 | mTOR |
| CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin-resistant signaling and the growth of glioblastomas in vitro and in vivo. | ||
| M28992 | RapaLink-1 | mTOR |
| RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin with MLN0128 by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity. | ||
| M29096 | eCF309 | mTOR |
| eCF309 is a potent and highly selective mTOR inhibitor with remarkably low off-target activities (IC50 = 10-15 nM, both in vitro and in cells). | ||
| M29584 | RMC-6272 | mTOR |
| RM-006 | ||
| RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors. | ||
| M43387 | SN32976 | PI3K |
| SN32976 is a potent and selective class I PI3K and mTOR inhibitor with IC50s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. | ||
| M43389 | FD274 | PI3K |
| FD274 is a highly potent PI3K/mTOR dual inhibitor with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
